Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Valneva SENASDAQ: VALN

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense declines year over year

Q1 FY2026 income tax expense of €824K fell 44.1% year over year, ahead of the -81.0% change in trailing-twelve-month income tax expense.

Context

  • Income tax expense amounted to 0.6% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -44.1% holds above the trailing-twelve-month pace of -81.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€824K+177.7% QoQ
Last fiscal yearDec 2025
€1.07M+41.0% YoY
LTMMar 2026
€423K-81.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.1%——
1 year+41.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

EUR · from the income statement

Latest · FY2025
1.07M EUR
Year-over-year change
+41.0%
4-year CAGR
-25.3%

Income Tax Expense vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -81.0% is the 4th highest of 5, against a peer median of +113.2%.
  • Income tax expense amounts to 0.3% of revenue for VALN, versus a peer median of 0.3%.
VALN Competitors
Income Tax Expense for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$60M USD+262.2%-64.6%2.4%
NVAXNovavax, Inc.LTM Mar 2026$1.65M USD-83.2%-24.3%0.3%
VALNValneva SELTM Mar 2026€423K EUR-81.0%—0.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$371K USD+126.4%-90.3%0.6%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 USD+100.0%—0.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
IBRXImmunityBio, Inc.LTM Sep 2026-$144K USD——0.1%
Peer median (excluding VALN) —+113.2%-64.6%0.3%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.